𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia

✍ Scribed by J. D. Roberts; W. B. Ershler; B. H. Tindle; J. A. Stewart

Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
351 KB
Volume
56
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Seven patients with a myelodysplastic syndrome or "smoldering" acute myelogenous leukemia were treated with cytosine arabinoside in low dosage. Four patients experienced transient, partial responses characterized by improved peripheral blood counts, cessation of transfusion requirements, and a decreased incidence of infection. Treatment was associated with significant, transient hematologic toxicity. The appropriate clinical role of low-dose cytosine arabinoside remains uncertain.

πŸ“œ SIMILAR VOLUMES

High dose cytosine arabinoside (HDARAC)
High dose cytosine arabinoside (HDARAC) in refractory acute leukemia
✍ Seth A. Rudnick; Edwin C. Cadman; Robert L. Capizzi; Roland T. Skeel; Joseph R. πŸ“‚ Article πŸ“… 1979 πŸ› John Wiley and Sons 🌐 English βš– 415 KB πŸ‘ 2 views

Thirteen leukemic patients with disease refractory to conventional chemotherapy were treated with 1.0 to 7.5 g/m2 of Cytosine Arabinoside (Ara-C) over 29 drug cycles. Drug infusions were spaced at 12-hour intervals; a maximum of four doses was administered over 36 hours. After single dose tolerance